Buckley L M, Leib E S, Cartularo K S, Vacek P M, Cooper S M
Medical College of Virginia, Richmond, USA.
Ann Intern Med. 1996 Dec 15;125(12):961-8. doi: 10.7326/0003-4819-125-12-199612150-00004.
Therapy with low-dose corticosteroids is commonly used to treat allergic and autoimmune diseases. Long-term use of corticosteroids can lead to loss of bone mineral density and higher risk for vertebral fractures. Calcium and vitamin D3 supplementation is rational therapy for minimizing bone loss, but little evidence for its effectiveness exists.
To assess 1) the effects of supplemental calcium and vitamin D3 on bone mineral density of patients with rheumatoid arthritis and 2) the relation between the effects of this supplementation and corticosteroid use.
2-year randomized, double-blind, placebo-controlled trial.
University outpatient-care facility.
96 patients with rheumatoid arthritis, 65 of whom were receiving treatment with corticosteroids (mean dosage, 5.6 mg/d).
Calcium carbonate (1000 mg/d) and vitamin D3 (500 IU/d) or placebo.
Bone mineral densities of the lumbar spine and femur were determined annually.
Patients receiving prednisone therapy who were given placebo lost bone mineral density in the lumbar spine and trochanter at a rate of 2.0% and 0.9% per year, respectively. Patients receiving prednisone therapy who were given calcium and vitamin D3 gained bone mineral density in the lumbar spine and trochanter at a rate of 0.72% (P = 0.005) and 0.85% (P = 0.024) per year, respectively. In patients receiving prednisone therapy, bone mineral densities of the femoral neck and the Ward triangle did not increase significantly with calcium and vitamin D3. Calcium and vitamin D3 did not improve bone mineral density at any site in patients who were not receiving corticosteroids.
Calcium and vitamin D3 prevented loss of bone mineral density in the lumbar spine and trochanter in patients with rheumatoid arthritis who were treated with low-dose corticosteroids.
低剂量皮质类固醇疗法常用于治疗过敏性和自身免疫性疾病。长期使用皮质类固醇会导致骨矿物质密度降低和椎体骨折风险增加。补充钙和维生素D3是减少骨质流失的合理疗法,但几乎没有证据表明其有效性。
评估1)补充钙和维生素D3对类风湿关节炎患者骨矿物质密度的影响,以及2)这种补充疗法的效果与皮质类固醇使用之间的关系。
为期2年的随机、双盲、安慰剂对照试验。
大学门诊护理机构。
96例类风湿关节炎患者,其中65例正在接受皮质类固醇治疗(平均剂量为5.6毫克/天)。
碳酸钙(1000毫克/天)和维生素D3(500国际单位/天)或安慰剂。
每年测定腰椎和股骨的骨矿物质密度。
接受泼尼松治疗并服用安慰剂的患者,腰椎和大转子处的骨矿物质密度每年分别以2.0%和0.9%的速率下降。接受泼尼松治疗并补充钙和维生素D3的患者,腰椎和大转子处的骨矿物质密度每年分别以0.72%(P = 0.005)和0.85%(P = 0.024)的速率增加。在接受泼尼松治疗的患者中,股骨颈和沃德三角区的骨矿物质密度在补充钙和维生素D3后未显著增加。在未接受皮质类固醇治疗的患者中,钙和维生素D3在任何部位均未改善骨矿物质密度。
钙和维生素D3可预防接受低剂量皮质类固醇治疗的类风湿关节炎患者腰椎和大转子处的骨矿物质密度流失。